Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Other Operating Expenses: 2023-2024

Historic Other Operating Expenses for Immunome (IMNM) over the last 1 years, with Dec 2024 value amounting to $27.4 million.

  • Immunome's Other Operating Expenses fell 66.12% to $27.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $152.3 million, marking a year-over-year change of. This contributed to the annual value of $152.3 million for FY2024, which is 88.54% up from last year.
  • As of Q4 2024, Immunome's Other Operating Expenses stood at $27.4 million, which was up 308.17% from $6.7 million recorded in Q3 2024.
  • In the past 5 years, Immunome's Other Operating Expenses registered a high of $112.0 million during Q1 2024, and its lowest value of $6.3 million during Q2 2024.
  • Moreover, its 2-year median value for Other Operating Expenses was $27.4 million (2024), whereas its average is $46.6 million.
  • Data for Immunome's Other Operating Expenses shows a maximum YoY slumped of 66.12% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Immunome's Other Operating Expenses stood at $80.8 million in 2023, then plummeted by 66.12% to $27.4 million in 2024.
  • Its Other Operating Expenses stands at $27.4 million for Q4 2024, versus $6.7 million for Q3 2024 and $6.3 million for Q2 2024.